Profitable Growth - in full compliance!

The overall business focus of SOLVING is the pragmatic and hands-on support of our customers in systematically identifying and exploiting growth potentials.


We have developed a very specific approach that leads to a rapid time to benefit, tangible and lasting top-and bottom-line impact.


All enabling areas will be aligned with the critical growth factors in order to  exploit the defined growth-areas and growth sources.


Our international and operative experience assures that the growth initiatives can and will be implemented and are easily accepted in the organization.

PharmaTimes: News RSS

CR UK forms £30m partnership with EU cancer charities (Do, 20 Sep 2018)
Cancer Research UK is partnering with European cancer research charities AIRC (Associazione Italiana per la Ricerca sul Cancro) and FC AECC (Asociación Española Contra el Cáncer) to invest around £30 million in six international collaborations aiming to accelerate progress in translational research.
>> mehr lesen

Setback for Pharming’s bid to expand use of Ruconest (Do, 20 Sep 2018)
US regulators have turned down Pharming’s application to expand the approved uses of Ruconest to include prophylaxis in patients with hereditary angioedema (HAE).
>> mehr lesen

EU green light for new Humira biosimilar (Do, 20 Sep 2018)
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.
>> mehr lesen